azacitidine has been researched along with daunorubicin in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (37.29) | 18.7374 |
| 1990's | 13 (22.03) | 18.2507 |
| 2000's | 5 (8.47) | 29.6817 |
| 2010's | 12 (20.34) | 24.3611 |
| 2020's | 7 (11.86) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Furusawa, E; Furusawa, S; Lee, JY; Suzuki, N | 1 |
| Comelli, A; Massimo, L | 1 |
| Wiernik, PH | 1 |
| Bear, RA; Garvey, MB; Ho, M | 1 |
| Chabner, BA; Myers, CE; Oliverio, VT | 1 |
| Cassileth, PA; Cooper, RA; Katz, ME; Petrillo, MH | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Gray, RG; Rees, JK | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Heinemann, V; Jehn, U | 1 |
| Champlin, R; Gajewski, J; Ho, W; Landaw, E; Nimer, S; Schiller, G; Vollset, S; Winston, D | 1 |
| Boyett, J; Kitchens, CS; Kramer, BS; Noyes, WD; Oblon, DJ; Ross, W; Weiner, RS | 1 |
| Lampkin, BC | 1 |
| Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Burnison, M; Champlin, R; Decker, R; Gale, RP; Greenberg, P; Ho, W; Holly, FE; Winston, D | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Baehner, RL; Buckley, JD; Chard, RL; Hammond, GD; Lampkin, BC; Nesbit, ME; Woods, WG | 1 |
| Jehn, U; Zittoun, R | 1 |
| Tobey, RA | 1 |
| Cihák, A; Harrap, KR; Veselý, J | 1 |
| Cabanillas, F | 1 |
| Bloomfield, CD; Coleman, M; Gottlieb, AJ; Greenberg, MS; Peterson, BA | 1 |
| Chard, RL | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Go, B; Gordon, DS; Meyer, L; Raney, MR; Vogler, WR; Winton, EF | 1 |
| Endo, T; Fukumaki, Y; Ishibashi, Y; Okano, H; Shiokawa, S | 1 |
| Jehn, U | 1 |
| Bartolucci, AA; Moore, JO; Omura, GA; Stagg, M; Volger, WR; Weiner, RS | 1 |
| Di Leone, L; Fernandes, MS; Gerhardt, LM; Kalakun, L; Loitzembauer, B; Moschen, M; Schaan, MD; Schwartsmann, G | 1 |
| deSilva, M; El-Osta, A; Hu, XF; Kantharidis, P; Nadalin, G; Parkin, JD; Slater, A; Wall, DM; Zalcberg, JR | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Karp, J | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Hou, CF; Luo, J; Ma, LM | 1 |
| Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Rybka, J; Tukiendorf, A | 1 |
| Baldus, CD; Berdel, WE; Brümmendorf, TH; Butterfaß-Bahloul, T; Dugas, M; Ehninger, G; Eveslage, M; Frickhofen, N; Gerss, J; Giagounidis, A; Görner, M; Götze, K; Hänel, M; Herr, W; Kaiser, U; Kaufmann, M; Kiani, A; Kiehl, M; Koschmieder, A; Koschmieder, S; Krause, SW; Krug, U; Kunzmann, V; Link, H; Müller-Tidow, C; Naumann, R; Neubauer, A; Noppeney, R; Peceny, R; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schmitz, N; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Thiem, U; Tschanter, P; Wagner, R | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
6 review(s) available for azacitidine and daunorubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Cycle; Child; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia; Methotrexate; Mitotic Index; Neoplastic Stem Cells; Prednisone; Prognosis; Vincristine | 1985 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
23 trial(s) available for azacitidine and daunorubicin
| Article | Year |
|---|---|
Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis | 1990 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Vincristine | 1989 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
Studies with anthracyclines in pediatric acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Azacitidine; Child; Child, Preschool; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Middle Aged; Naphthacenes; Random Allocation; Sex Factors | 1981 |
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BCG Vaccine; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyguanosine; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Thioguanine; Thionucleosides; United States | 1984 |
Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Opportunistic Infections; Patient Acceptance of Health Care; Preleukemia; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1994 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Remission Induction; Thioguanine | 1995 |
Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Daunorubicin; Decitabine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2012 |
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2016 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
30 other study(ies) available for azacitidine and daunorubicin
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combination chemotherapy of Rauscher leukemia and ascites tumors by narcissus alkaloid with standard drugs and effect on cellular immunity.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Blood Cells; Carcinoma, Ehrlich Tumor; Carmustine; Cells, Cultured; Cyclophosphamide; Dactinomycin; Daunorubicin; Drug Synergism; Drug Therapy, Combination; Emetine; Leukemia, Experimental; Leukemia, Lymphoid; Methotrexate; Mice; Mice, Inbred BALB C; Plants, Medicinal; Rauscher Virus; Spleen; Streptonigrin; Vincristine | 1975 |
[New drugs for the therapy of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin | 1975 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
Topics: Adult; Azacitidine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Phosphates; Prednisone; Pregnancy; Pregnancy Complications; Thioguanine; Vincristine | 1976 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leucovorin; Lung; Male; Methotrexate; Neoplasms; Nitrosourea Compounds; Procarbazine; Triazenes; Vinblastine; Vincristine | 1977 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Thioguanine | 1985 |
Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse.
Topics: Animals; Antineoplastic Agents; Autoradiography; Azacitidine; Camptothecin; Cell Division; Cell Line; Cricetinae; Cytarabine; Daunorubicin; DNA; DNA Replication; Doxorubicin; Mitosis; Plicamycin; Thymidine; Tritium | 1972 |
Enhancement of rat liver uridine kinase activity by various metabolic inhibitors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Azauridine; Carbon Radioisotopes; Cell-Free System; Cycloheximide; Dactinomycin; Daunorubicin; Diet; Doxorubicin; In Vitro Techniques; Liver; Male; Orotic Acid; Phosphotransferases; Puromycin; Pyrimidines; Rats; Stimulation, Chemical; Thioacetamide; Thymus Gland; Uridine | 1974 |
5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.
Topics: Acute Disease; Adult; Aged; Azacitidine; Bone Marrow; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney; Leukemia; Liver; Male; Middle Aged; Pilot Projects | 1982 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
Differential induction of adult and fetal globin gene expression in the human CML cell subline KU-812F/33.
Topics: Azacitidine; Cell Differentiation; Daunorubicin; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Erythrocytes; Fetal Hemoglobin; Globins; Hemin; Hemoglobins; Humans; Isoelectric Focusing; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Succinates; Succinic Acid; Tumor Cells, Cultured | 1994 |
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Blotting, Southern; Daunorubicin; Decitabine; Dinucleoside Phosphates; DNA Methylation; Drug Resistance, Multiple; Epirubicin; Exons; Humans; Introns; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Promoter Regions, Genetic; Restriction Mapping; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
[Effect of proliferation inhibition and PTEN gene expression induced by decitabine combined with daunorubicin on HL-60 cell line].
Topics: Azacitidine; Cell Proliferation; Daunorubicin; Decitabine; HL-60 Cells; Humans; PTEN Phosphohydrolase | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2015 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |